Examkin

Soru

Zorluk: ZorEnd-of-Life and Palliative Care

A 54-year-old woman with widely metastatic gastric adenocarcinoma presents to the emergency department with a 4-day history of progressively worsening crampy abdominal pain, persistent nausea, and large-volume bilious emesis. She reports that she has not passed flatus or had a bowel movement in 5 days. Her vital signs are temperature 37.1°C (98.8°F), pulse 108/min, blood pressure 102/64 mm Hg, and respiratory rate 18/min. Physical examination reveals a markedly distended, tympanic abdomen that is diffusely tender without rigidity or rebound. Bowel sounds are high-pitched and infrequent. Computed tomography of the abdomen and pelvis demonstrates a high-grade mechanical small bowel obstruction with at least three distinct transition points due to massive peritoneal carcinomatosis. The surgical oncology team evaluates the patient and determines she is not a candidate for operative intervention or endoscopic stenting due to the multifocal nature of the obstruction and her declining functional status.

The patient is alert, oriented, and demonstrates a clear understanding of her terminal prognosis, which is estimated to be 2 to 4 weeks. She explicitly states, "I know my time is short and I want to be kept comfortable, but please, no more tubes down my nose or throat." Her pain is currently partially managed with an intravenous fentanyl infusion, but her nausea and colicky pain remain severe. Which of the following is the most appropriate next step in the management of this patient's symptoms?

  1. Initiate intravenous dexamethasone, subcutaneous octreotide, and intravenous haloperidolCevap
  2. B
    Initiate intravenous metoclopramide and an oral polyethylene glycol solution
  3. C
    Order a magnetic resonance imaging scan of the abdomen with intravenous contrast to delineate the transition points
  4. D
    Override the patient's refusal and place a nasogastric tube for emergency gastrointestinal decompression
  5. E
    Transfer the patient to the intensive care unit for continuous hemodynamic monitoring and aggressive fluid resuscitation

Cevap

Initiate intravenous dexamethasone, subcutaneous octreotide, and intravenous haloperidol.
The correct response addresses the complex symptom burden of an inoperable malignant bowel obstruction (MBO) using a targeted, multi-agent pharmacological approach that respects the patient's goals of care and refusal of invasive devices. Corticosteroids (e.g., intravenous dexamethasone) are utilized to decrease peritumoral inflammatory edema, which can partially relieve the obstruction. Somatostatin analogs (e.g., subcutaneous octreotide) are highly effective at decreasing the volume of gastrointestinal, pancreatic, and biliary secretions, thereby reducing intraluminal pressure, distension, and vomiting. Typical antipsychotics (e.g., intravenous haloperidol) act as potent centrally-acting antiemetics by blocking dopamine (D2) receptors in the chemoreceptor trigger zone, without the dangerous prokinetic effects seen with other antiemetics.

Adım Adım Çözüm

1
Assess the clinical scenario and the patient's goals of care.
The patient has an inoperable, terminal malignant bowel obstruction (MBO) and has explicitly refused nasogastric (NG) tube decompression. She has decision-making capacity and desires comfort care.
Establishing the clinical limitations (inoperable) and patient preferences (no NG tube) directs the management strategy entirely toward pharmacological symptom control.
2
Identify the pathophysiological drivers of symptoms in malignant bowel obstruction.
Symptoms are driven by peritumoral inflammatory edema, accumulation of massive gastrointestinal intraluminal secretions, and centrally mediated nausea from bowel distension.
Targeting these specific mechanisms is required to provide relief without utilizing mechanical decompression.
3
Select the appropriate pharmacological agents to target these drivers.
Dexamethasone reduces peritumoral edema; octreotide profoundly decreases gastrointestinal secretions; haloperidol provides centrally-acting antiemetic effects without stimulating gut motility.
This specific combination of medications represents the standard of care for medical management of inoperable MBO when an NG tube cannot be used.

Anahtar Kavram

Pharmacological management of malignant bowel obstruction at the end of life requires a combination of corticosteroids, somatostatin analogs, and antiemetics lacking prokinetic activity.
Bu soruyu puanla

Konular

End-of-Life and Palliative Care

Bu konudan daha fazla soru